M 6495

Drug Profile

M 6495

Alternative Names: ALX 1141; M 6495

Latest Information Update: 07 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ablynx; Merck KGaA
  • Class Anti-inflammatories; Antirheumatics; Proteins; Single-domain antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Osteoarthritis

Most Recent Events

  • 16 Nov 2017 Phase-I clinical trials in Osteoarthritis (Parenteral) before November 2017
  • 04 Sep 2017 Phase-I clinical trials (In Volunteers) (SC) in Denmark(NCT03224702)
  • 24 Aug 2017 Merck plans a phase I trial for ALX 1141 for Osteoarthritis in second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top